SCHEMBL3563670

SCHEMBL3563670

O=[N+]([O-])c1cc2c(c3ccc(S(=O)(=O)NO)cc13)C(CCl)CN2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
MMP1 P03956 4/20 0.45
MMP2 P08253 4/20 0.45
MMP9 P14780 4/20 0.45
MMP8 P22894 4/20 0.45
MMP13 P45452 4/20 0.45
VCAM1 P19320 3/20 0.36
ALDH1A1 P00352 3/20 0.34
HPGD P15428 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALDH3A1 P30838 1/20 0.32
MAPK1 P28482 1/20 0.32
THRB P10828 1/20 0.32
F2 P00734 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565636 0.89 MAPK1 (0.39) VCAM1ALDH1A1TDP1MAPK1MAPT
SCHEMBL13344966 0.87 CA1 (0.37) CA1CA2MMP1MMP2MMP9
SCHEMBL3564884 0.86 VCAM1 (0.36) VCAM1ALDH1A1HPGDTDP1ALDH3A1
SCHEMBL13369379 0.86 KMT2A (0.38) VCAM1ALDH1A1HPGDTDP1ALDH3A1
SCHEMBL3562579 0.86 VCAM1 (0.45) CA1CA2VCAM1ALDH1A1TDP1
SCHEMBL3560139 0.82 ALOX5 (0.49) CA1CA2VCAM1THRB
SCHEMBL3565777 0.81 KMT2A (0.38) VCAM1ALDH1A1HPGDTDP1ALDH3A1
SCHEMBL3568374 0.81 ALDH1A1 (0.37) ALDH1A1HPGDTDP1MAPK1LMNA
SCHEMBL13460619 0.80 TSHR (0.38) ALDH1A1TDP1MAPT
SCHEMBL3563974 0.79 CTSB (0.41) ALDH1A1HPGDTDP1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A CA1 612/4885CA2 492/4885MMP1 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.